MetaCap

Amarin (AMRN) vs Indaptus Therapeutics (INDP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Indaptus Therapeutics (INDP) has outperformed Amarin (AMRN) over the past year, gaining 52.4% versus a loss of 35.5%. Over five years, AMRN leads with a -85.5% price change compared with -98.3% for INDP. Amarin is the larger company by market cap ($444.4 million vs $433.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRN-35.47%INDP+52.43%
+167%+54%-60%
Nov 21, 20251 yearNov 20, 2026
AMRN-86.45%INDP-98.22%
+14%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRN versus INDP key metrics
MetricAMRNINDP
Share price$10.57$2.82
Market cap$444.39M$433.16M
1-day change-6.13%-9.90%
YTD return-24.28%-3.09%
1-year return-35.47%+52.43%
5-year return-85.48%-98.26%
Forward P/E10.79—
EPS (TTM)$-0.80$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$213.65M—
Revenue growth (YoY)-6.55%—
Net income (latest FY)$-38.80M$-20.85M
Gross margin56.57%—
Operating margin-23.48%—
Net margin-18.16%—
52-week high$17.31$5.96
52-week low$10.56$0.92
Distance from 52-week high-38.94%-52.68%
Analyst consensusnone—
Avg. price target upside+22.99%—
Average volume79.50K712.87K
Shares outstanding42.04M153.60M
Employees805
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INDP has outperformed AMRN by 87.9 percentage points over the past year.

About Amarin

AMRN stock →

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Indaptus Therapeutics

INDP stock →

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

AMRN vs INDP FAQ

Which is bigger, Amarin or Indaptus Therapeutics?

Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $433.16M for Indaptus Therapeutics (INDP).

Which stock has performed better over the past year, AMRN or INDP?

INDP returned +52.43% over the past 12 months, compared with -35.47% for AMRN (price return, excluding dividends). Past performance does not predict future results.

Are Amarin and Indaptus Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons